Published in Anti-Infectives Week, October 31st, 2005
Anthim has been granted "fast track" status (May 6, 2005) by the U.S. Food & Drug Administration (FDA) and this study will begin in the coming weeks.
The company also reported that it has initiated manufacturing scale-up to produce Anthim in commercial quantities in the event of U.S. government purchase for the Strategic National Stockpile.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.